一般演題（口演）39 ゲノム・その他

[O39-5] FURVENT：Ph3 trial of firmonertinib vs chemo as first-line treatment for EGFR ex20ins NSCLC

^○Koichi Goto¹, Koichi Azuma², Kenichi Chikamori³, Yoshihiro Hattori⁴, Yukio Hosomi⁵, Hiroki Izumi¹, Terufumi Kato⁶, Takayasu Kurata⁷, Nobuaki Mamesaya⁸, Tomoyasu Mimori⁹, Masahide Oki¹⁰, Shunichi Sugawara¹¹, Takayuki Takahama¹², Hiroshi Yokouchi¹³, Yong Jiang¹⁴, Jerry Y Hsu¹⁵ (1.National Cancer Center Hospital East, 2.Kurume University Hospital, 3.National Hospital Organization Yamaguchi Ube Medical Center, 4.Hyogo Cancer Center, 5.Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, 6.Kanagawa Cancer Center, 7.Kansai Medical University Hospital, 8.Shizuoka Cancer Center, 9.Juntendo University Hospital, 10.National Hospital Organization Nagoya Medical Center, 11.Sendai Kousei Hospital, 12.Kindai University Hospital, 13.NHO Hokkaido Cancer Center, 14.Shanghai Allist Pharmaceuticals, 15.ArriVent Biopharma)

アンコール演題